Trial of d-alpha-tocopherol in Huntington's disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Evidence suggests that the neuropathology of Huntington's disease, a neuropsychiatric disorder due to a mutation on chromosome 4, results from excessive activation of glutamate-gated ion channels, which kills neurons by oxidative stress. Therefore, the authors hypothesized that alpha-tocopherol, which reduces oxyradical damage to cell membranes, might slow the course of Huntington's disease. METHOD: A prospective, double-blind; placebo-controlled study of high-dose d-alpha-tocopherol treatment was carried out with a cohort of 73 patients with Huntington's disease who were randomly assigned to either d-alpha-tocopherol or placebo. Patients were monitored for changes in neurologic and neuropsychologic symptoms. RESULTS: Treatment with d-alpha-tocopherol had no effect on neurologic and neuropsychiatric symptoms in the treatment group overall. However, post hoc analysis revealed a significant selective therapeutic effect on neurologic symptoms for patients early in the course of the disorder. CONCLUSIONS: Antioxidant therapy may slow the rate of motor decline early in the course of Huntington's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
Coyle, J. T., & Puttfarcken, P. (1993) · Science · doi:10.1126/science.7901908 · Cited by 3,762
Self-citationA Modified Card Sorting Test Sensitive to Frontal Lobe Defects
Nelson, H. E. (1976) · Cortex · doi:10.1016/s0010-9452(76)80035-4 · Cited by 2,454
Cited by
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007176.pub2 · Cited by 924
Gilgun-Sherki, Y., Melamed, E., & Offen, D. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00019-3 · Cited by 838
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 359
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007176 · Cited by 302
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 295
Calabrese, V., Bates, T. E., & Stella, A. M. G. (2000) · Neurochemical Research · doi:10.1023/a:1007604414773 · Cited by 284
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Calabrese, V., Scapagnini, G., Giuffrida Stella, A. M., Bates, T. E., & Clark, J. B. (2001) · Neurochemical Research · doi:10.1023/a:1010955807739 · Cited by 263
“In addition to AD, consideration is being given for the use of vitamin E in other neurodegenerative disorders, including Huntington’s disease (178) and amyotrophic lateral sclerosis (179).”
BackgroundAntioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia
Tsai, G., Goff, D. C., Chang, R. W., Flood, J., Baer, L., & Coyle, J. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1207 · Cited by 243
Vitamin E and All-Cause Mortality: A Meta-Analysis
L. Abner, E., A. Schmitt, F., S. Mendiondo, M., L. Marcum, J., & J. Kryscio, R. (2011) · Current Aging Sciencee · doi:10.2174/1874609811104020158 · Cited by 209
Increased basal ganglia iron levels in Huntington disease
Bartzokis, G., Cummings, J., Perlman, S., Hance, D. B., & Mintz, J. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.569 · Cited by 183
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub4 · Cited by 104
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
A controlled trial of idebenone in Huntington's disease
Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., Folstein, M. F., Brandt, J., Ross, C. A., & Folstein, S. E. (1996) · Movement Disorders · doi:10.1002/mds.870110510 · Cited by 97
Self-citation
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1995-12-01
- Volume
- 152
- Issue
- 12
- Pages
- 1771-1775
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W979646749
- Cited by
- 139
- References
- 2
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.